GHK-Cu is not a recently discovered compound — Loren Pickart first isolated it from human plasma albumin in 1973. What is new is the scale at which modern gene-expression profiling has mapped its reach. Investigators studying neurodegeneration, cognitive ageing, DNA integrity, and oxidative stress have turned to GHK-Cu because the mechanism is unusually broad and the molecule itself is endogenous. This review synthesises the three core published sources on GHK-Cu, explains why intranasal delivery is drawing researcher interest for cognitive research contexts, and describes exactly where to buy GHK-Cu UAE in HPLC-verified, lot-COA research grade — in stock now at REVIVE LAB UAE in both 50 mg and 100 mg vials.
GHK-Cu is a tripeptide — glycine, histidine, lysine — chelated to a copper(II) ion. At physiological pH the copper complex is stable; the peptide component acts as a high-affinity carrier that increases the bioavailability of ionic copper to tissues while simultaneously engaging its own transcriptional signalling cascade, partly through copper-dependent enzymes (superoxide dismutase, lysyl oxidase, cytochrome c oxidase) and partly through direct modulation of transcription factor activity. This dual mechanism is what produces the unusually wide genomic map documented in Pickart & Margolina 2018.
Human plasma GHK-Cu concentrations are highest in young adults — approximately 200 ng/mL at age 20 — and decline sharply with age; by age 60, levels have fallen by an estimated 60-70%. This depletion pattern is why investigators frame GHK-Cu research in the context of biological ageing and cellular maintenance rather than targeting a single pathology.
| Property | Detail |
|---|---|
| Full name | Glycyl-L-histidyl-L-lysine copper(II) salt |
| Molecular weight | ~340 Da (free peptide); ~403 Da as Cu²♠ complex |
| Source | Naturally occurring in human plasma, saliva, urine |
| Plasma concentration (young adult) | ~200 ng/mL; falls ~60-70% by age 60 |
| Available strengths (REVIVE LAB UAE) | 50 mg vial / 100 mg vial |
| Storage (lyophilized) | 2-8°C, protected from light |
The pivotal modern reference for GHK-Cu researchers is Pickart & Margolina's 2018 review in Cosmetics — a paper that consolidated decades of cell-biology data and repositioned GHK-Cu as a broad genomic activator rather than a tissue-specific growth factor. Using gene-expression arrays and bioinformatic network analysis, the authors documented GHK-Cu's influence across more than 4,000 human genes, organised into functionally coherent clusters:
The cognitive research angle is grounded primarily in the neurotrophin data. BDNF is the canonical mediator of synaptic plasticity and adult neurogenesis in the hippocampus and prefrontal cortex — two structures central to age-related cognitive decline. The finding that GHK-Cu upregulates BDNF-related transcripts in cell-expression models is, for investigators in neuroprotection research, one of the more compelling signals in the Pickart 2018 data set. It does not demonstrate cognitive benefit in intact organisms — but it frames the intranasal delivery hypothesis as mechanistically coherent and worthy of formal investigation.
The Campbell et al. 2012 paper in BMC Genomics is the dedicated gene-array study most cited in the context of GHK-Cu's potential neuroprotective and oncostatic research profiles. Investigators used a systems-biology approach to map GHK-Cu's transcriptional effects and identified upregulation of a cluster of tumour-suppressor and DNA-repair gene transcripts — including components of homologous recombination repair pathways, checkpoint-signalling nodes, and mismatch-repair gene networks.
The implication for cognitive research is indirect but mechanistically coherent. Post-mitotic neurons cannot renew themselves by division; their DNA-repair capacity therefore becomes unusually critical over decades, and accumulated neuronal DNA damage is one of the leading molecular hypotheses for late-onset neurodegeneration. If GHK-Cu activates DNA-repair gene networks in neuronal cell models — the logical extension of the Campbell 2012 findings — then delivering the peptide directly to CNS tissue via an intranasal route, rather than diluting it through systemic circulation, becomes a sensible experimental priority.
| Gene Cluster Category | Direction | Research Relevance |
|---|---|---|
| Homologous recombination repair | Upregulated | Double-strand DNA break resolution |
| Checkpoint-signalling nodes | Upregulated | Damage surveillance and cell-cycle arrest |
| Mismatch-repair (MMR) transcripts | Upregulated | Replication-error correction |
| Tumour-suppressor gene networks | Upregulated | Apoptotic surveillance |
| Pro-inflammatory cytokine transcripts | Downregulated | Anti-neuroinflammation hypothesis |
The blood-brain barrier (BBB) is the standard constraint on peptide CNS delivery. Most peptides do not efficiently cross the BBB when delivered systemically, because the tight junctions of CNS endothelial cells exclude molecules that lack specific transporter recognition. GHK-Cu as a free peptide sits at approximately 340 Da — near but not reliably within the passive-diffusion window — and CNS uptake after systemic dosing is low in most models.
The intranasal route bypasses this constraint through a different anatomy. The olfactory epithelium and the trigeminal nerve branches innervating the nasal mucosa both provide axonal transport pathways directly into the CNS — depositing molecule cargo in the olfactory bulb, limbic structures, and brainstem pathways within minutes of nasal administration, without requiring BBB transit. This nose-to-brain mechanism has been validated in animal models for insulin, IGF-1, BDNF, and several small peptides, establishing the anatomical proof-of-concept that investigators now apply to GHK-Cu.
For GHK-Cu specifically, the intranasal research hypothesis converges from two directions: the Pickart 2018 neurotrophin and anti-inflammatory genomic data (providing a mechanism relevant to CNS biology) and the anatomical advantage of the olfactory route (providing CNS delivery without the systemic dilution and BBB exclusion that limit subcutaneous approaches). Investigators studying cognitive ageing, neuroinflammation, and post-injury neuroprotection have explicitly framed GHK-Cu intranasal protocols as a direction worth formal controlled investigation.
| Parameter | Intranasal | Subcutaneous |
|---|---|---|
| BBB bypass | Yes — olfactory/trigeminal axonal transport | No — relies on systemic circulation |
| CNS tissue exposure | Higher, faster (minutes) | Lower; time-lagged (hours) |
| Systemic exposure | Lower | Higher |
| Mucosal absorption variables | Present (pH, mucus, ciliary clearance) | Absent |
| Primary research application | Cognitive ageing, neuroinflammation, neuroprotection | Wound healing, skin, peripheral tissue remodelling |
Before modern genomics, the GHK-Cu evidence base was built in wound-healing biology. Pickart's 2008 review in Advances in Wound Care consolidated the pre-genomic literature and documented GHK-Cu's role across several interconnected tissue-repair processes:
The wound-healing literature is where GHK-Cu has its strongest published evidence base, including topical-application trials showing measurable effects on wound closure and scar reduction. This earlier body of work matters for researchers evaluating GHK-Cu's broader research profile because it mechanistically anchors the Pickart 2018 and Campbell 2012 claims: the same collagen-synthesis, anti-inflammatory, and angiogenic pathways that accelerate wound repair in peripheral tissue are those hypothesised to support neuronal tissue maintenance in the CNS context — particularly when delivery is optimised through the intranasal route.
Investigators working with GHK-Cu from REVIVE LAB UAE have access to two vial sizes — 50 mg and 100 mg — both lyophilized and requiring reconstitution before use. Sterile saline (0.9% NaCl) is the standard reconstitution vehicle for intranasal research protocols; bacteriostatic water extends usable life for multi-week subcutaneous or topical applications.
| Vial Size | Reconstitution Volume | Resulting Concentration | Research Application Context |
|---|---|---|---|
| GHK-Cu 50 mg | 5 mL sterile saline | 10 mg/mL | Concentrated topical or intranasal research stock |
| GHK-Cu 50 mg | 25 mL sterile saline | 2 mg/mL | Dilute intranasal delivery research protocols |
| GHK-Cu 100 mg | 10 mL sterile saline | 10 mg/mL | Extended-protocol stock, topical or systemic research |
| GHK-Cu 100 mg | 50 mL sterile saline | 2 mg/mL | Large-volume dilution or multi-route protocols |
Once reconstituted, vials should be held at 2-8°C, shielded from light, and used within 14 days. Lyophilized vials from REVIVE LAB UAE maintain peptide integrity at 2-8°C for the lot shelf life stated on the accompanying COA. Every lot is HPLC-tested and the purity documentation is available on request — this is the minimum standard for any research peptide where the genomic data is only as valid as the compound purity.
For UAE-based investigators, the practical sourcing question is straightforward: where can you get research-grade ghk-cu in stock UAE without waiting weeks for an overseas shipment that may have been compromised by uncontrolled transit temperatures? REVIVE LAB UAE maintains locally held Dubai stock of both 50 mg and 100 mg GHK-Cu vials and dispatches via cold-chain refrigerated courier to every emirate.
| Emirate / City | Delivery Window | Cash on Delivery | Cold-Chain Dispatch |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, JVC, Downtown, Palm, Jumeirah) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas Island, Saadiyat, Reem) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18-24 hours | Yes | Yes |
| Al Ain | Next-day, 24 hours | Yes | Yes |
Cash on delivery is available across all seven emirates — no upfront payment required. For researchers who prefer digital settlement, REVIVE LAB UAE now accepts USDT crypto pay (TRC20 via Binance Pay) with a 5% pre-pay discount; confirm your transaction ID on WhatsApp to trigger same-day dispatch. For ghk-cu same day Dubai orders, place before the daily dispatch cut-off and expect cold-pack vials within the same afternoon window.
REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched GHK-Cu across all 7 emirates — from locally held Dubai stock, not brokered from an offshore reseller. Every GHK-Cu batch is HPLC-tested to purity ≥99% before dispatch; the lot-level Certificate of Analysis is available on request. Vials are lyophilized, sealed under inert atmosphere, and shipped in validated cold-chain insulation that holds 2-8°C through any UAE summer transit, from the Dubai warehouse door to your research lab.
REVIVE LAB UAE covers the full research peptide stack: GHK-Cu is stocked alongside the site's three bestselling compounds — Retatrutide (GIP/GLP-1/glucagon triagonist), Tesamorelin (GHRH analog), and GHK-Cu itself — plus BPC-157, TB-500, MOTS-c, Semax, and NAD+. All shipments from REVIVE LAB UAE use plain, unbranded outer cartons as the default, with no reference to peptides or brand on the outer packaging.
Yes. REVIVE LAB UAE stocks GHK-Cu in both 50 mg and 100 mg vial sizes and dispatches same-day within Dubai for orders placed before the daily cut-off. Delivery to all seven emirates is available within 24 hours. All vials are HPLC-verified with lot-COA documentation and shipped in cold-chain insulated packaging. Cash on delivery is supported UAE-wide; USDT TRC20 crypto payment is accepted via Binance Pay with a 5% pre-pay discount.
REVIVE LAB UAE supplies lyophilized GHK-Cu vials tested to ≥99% purity by HPLC and issued with a lot-level Certificate of Analysis. The lyophilized format allows investigators to reconstitute to precise working concentrations using sterile saline — the standard vehicle for intranasal delivery research — and to control exactly what the preparation contains without stabiliser interference. Vials are dispatched in cold-chain packaging to preserve peptide integrity from warehouse to lab.
GHK-Cu has one of the broadest published genomic footprints of any single peptide in research literature — Pickart & Margolina 2018 documented modulation of more than 4,000 human genes, including BDNF-related neurotrophin clusters relevant to synaptic plasticity and age-related cognitive decline. For neuroprotective research, the intranasal route is investigated as a blood-brain barrier-bypassing delivery path via olfactory and trigeminal nerve anatomy — a distinct profile versus growth-hormone axis peptides like tesamorelin or GHRPs. REVIVE LAB UAE stocks GHK-Cu 50 mg and 100 mg alongside Retatrutide, Tesamorelin, BPC-157, and TB-500 for the complete peptides UAE research stack.